Competitor Analysis: Coagulation Factors

Published by	La Merie Publishing
Published	October, 2009	Product code	102247
Content info	126 Pages
Price	US $ 705 PDF by E-mail (Single User License) US $ 1410 PDF by E-mail (Site License) US $ 2115 PDF by E-mail (Global Site License)

Introduction
Related Reports

Competitor Analysis: Coagulation Factors published by La Merie Publishing in October, 2009. This report consists of 126 Pages and the price starts from US $ 705.

Introduction

Abstract

Report Statistics

Pages: 126
Release Date: October of 2009
Format: PDF

Product description

The present Competitive Intelligence Report about Coagulation Factors provides a competitor evaluation in the field of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of October 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The market size of recombinant and plasma-derived coagulation factor products exceeded US$ 7.5 bln in 2008, the majority (US$ 5.5 bln) generated by recombinant proteins. Replacement of plasma-derived coagulation factors by marketed recombinant molecules is ongoing and will further increase by new recombinant coagulation factors in development. In light of ongoing expiration of substance patents, about 40 new recombinant coagulation factor projects are in the pipeline indicating a changing marketplace over the next decade. New players are competing and will challenge established manufacturers and marketers of coagulation factor products.

Apart from recombinant products, plasma-derived coagulation factors still play a considerable role, albeit bovine derived products are considerably being challenged by human recombinant and plasma-derivd products. Coagulation factors not only are being used for systemic treatment of hereditary coagulation factor deficiencies, but also for topical or systemic treatment of bleedings.

The report includes a compilation of current active projects in research and development of topical and systemic coagulation factors obtained by purification of human plasma or by recombinant DNA technology. In addition, the report lists company-specific R&D pipelines of coagulation factors.

Competitor projects are listed in a tabular format providing information on: